Latest Ratios: P/E Ratio 10.8x · EV/EBITDA N/A · ROE 15.5%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $756M | $481M | $379M | $759M | $797M | $2.7B | $1.7B | $550M | $311M | $197M | $46M |
| Enterprise Value | $736M | $461M | $585M | $1.1B | $1.2B | $3.0B | $1.8B | $507M | $289M | $182M | $41M |
| P/E Ratio → | 10.76 | 6.86 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.29 | 2.73 | 1.63 | 3.20 | 3.58 | 12.21 | 21.51 | 16.19 | 15.85 | 16.50 | 6.00 |
| P/B Ratio | 1.50 | 0.96 | 0.94 | 1.55 | 1.43 | 4.23 | 4.42 | 4.35 | 8.07 | 11.03 | 8.11 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 334.42 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.62 | 2.51 | 4.76 | 5.37 | 13.50 | 22.71 | 14.94 | 14.70 | 15.24 | 5.40 |
| EV / EBITDA | — | — | — | — | 494.69 | 1242.97 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 42.6% | 43.8% | 43.4% | 43.4% | 46.2% | 51.1% | 52.2% | 49.9% | 40.4% |
| Operating Margin | -20.9% | -20.9% | -49.4% | -13.4% | -8.0% | -8.0% | -38.1% | -52.1% | -44.0% | -66.0% | -114.2% |
| Net Profit Margin | 39.9% | 39.9% | -42.7% | -15.7% | -123.8% | -123.8% | -41.5% | -54.0% | -48.7% | -66.1% | -170.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.5% | 15.5% | -22.4% | -7.1% | -46.0% | -53.8% | -12.8% | -22.2% | -33.9% | -67.0% | -245.8% |
| ROA | 9.6% | 9.6% | -12.0% | -3.7% | -25.6% | -33.1% | -9.5% | -19.0% | -24.9% | -55.7% | -168.4% |
| ROIC | -5.1% | -5.1% | -11.8% | -2.6% | -1.4% | -1.9% | -8.0% | -26.6% | -68.9% | -301.3% | -726.6% |
| ROCE | -6.2% | -6.2% | -14.8% | -3.3% | -1.7% | -2.2% | -9.3% | -19.2% | -24.1% | -65.9% | -161.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.46 | 0.46 | 0.62 | 0.85 | 0.78 | 0.67 | 0.34 | 0.04 | 0.38 | — | 0.11 |
| Debt / EBITDA | — | — | — | — | 180.28 | 176.61 | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | 0.51 | 0.76 | 0.72 | 0.45 | 0.25 | -0.34 | -0.59 | -0.84 | -0.81 |
| Net Debt / EBITDA | — | — | — | — | 165.14 | 119.09 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -15.59 | -15.59 | -17.05 | -4.71 | -57.40 | -57.40 | -11.79 | -12.37 | -136.69 | -502.02 | -98.88 |
Net cash position: cash ($250M) exceeds total debt ($231M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | 2.17 | 5.29 | 11.73 | 14.79 | 16.26 | 4.20 | 18.85 | 16.91 | 7.92 | 2.73 |
| Quick Ratio | 2.07 | 2.07 | 4.94 | 11.16 | 14.11 | 15.88 | 3.90 | 18.77 | 16.84 | 7.86 | 2.69 |
| Cash Ratio | 1.88 | 1.88 | 4.05 | 10.01 | 12.81 | 14.74 | 2.66 | 17.27 | 15.44 | 6.88 | -1247.16 |
| Asset Turnover | — | 0.23 | 0.33 | 0.25 | 0.21 | 0.20 | 0.14 | 0.25 | 0.35 | 0.59 | 0.95 |
| Inventory Turnover | 4.02 | 4.02 | 5.96 | 5.09 | 4.55 | 7.64 | 4.02 | 35.00 | 42.57 | 52.16 | 51.14 |
| Days Sales Outstanding | — | 69.11 | 71.63 | 64.72 | 71.91 | 64.62 | 145.53 | 76.33 | 65.90 | 49.63 | 56.83 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.3% | 14.6% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 1.3% | 2.1% | 0.0% | 0.0% | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.3% | 2.1% | 0.0% | 0.0% | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $50M | $49M | $49M | $46M | $46M | $39M | $33M | $28M | $23M | $14M |
Biotech funding cycle sensitivity
Based on reported figures, Cryoport trades at a P/S multiple of 4.56, which appears to discount the company's recent 24% revenue contraction while failing to account for the persistent negative operating margins that continue to weigh on the firm's long-term valuation prospects relative to broader industrial peers.
The current P/E of 11.43 is likely distorted by non-recurring gains, rendering it a poor indicator of core earning power. Investors should monitor whether the market's valuation premium for a 'pure-play' life sciences infrastructure provider can be sustained if revenue growth does not return to positive territory.
As reported in financial statements, Cryoport's ROIC has remained consistently negative, hovering around -1.5% in 2026Q1, which suggests that the company is currently failing to generate adequate returns on its invested capital compared to the cost of maintaining its specialized, capital-intensive global logistics infrastructure.
The persistent decay in ROIC indicates that the company's aggressive M&A strategy has not yet translated into operational synergies. This trend warrants further investigation into whether the current asset base is over-scaled for the prevailing level of clinical trial demand.
According to recent quarterly filings, the cash conversion cycle has fluctuated significantly, reaching 92 days in 2026Q1, which suggests that the company's ability to efficiently manage its inventory and receivables is being hampered by the inherent complexities of its specialized cold chain logistics service model.
The elevated DIO of 78 days indicates potential over-stocking of specialized dewars, which ties up liquidity that could otherwise be deployed for operational needs. This inefficiency appears to be a structural drag on the company's ability to optimize its cash flow during periods of revenue volatility.
Based on the provided balance sheet data, the current ratio of 2.09 in 2026Q1 suggests an adequate short-term liquidity position, yet this metric may be misleading given the company's ongoing negative operating margins and the high fixed-cost nature of its global supply chain center network.
While the current ratio appears healthy, the company's reliance on cash reserves to fund operations suggests that liquidity could deteriorate rapidly if revenue does not stabilize. Investors should monitor the burn rate closely, as the current cash position provides only a temporary cushion against ongoing operational losses.
The most commonly misapplied metric for Cryoport is the P/E ratio, which frequently obscures the company's underlying operational health by including non-recurring gains that do not reflect the core business's ability to generate sustainable, recurring cash flow from its specialized life sciences logistics services.
Analysts should instead focus on adjusted EBITDA or free cash flow, stripping out stock-based compensation and one-time acquisition impacts to reveal the true cash-generating capacity. Relying on headline net income may lead to an overly optimistic assessment of the company's ability to cover its high fixed-cost base.
Includes 30+ ratios · 23 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CYRX stock.
Cryoport, Inc.'s current P/E ratio is 10.8x. The historical average is 6.9x. This places it at the 100th percentile of its historical range.
Cryoport, Inc.'s return on equity (ROE) is 15.5%. The historical average is -129.6%.
Based on historical data, Cryoport, Inc. is trading at a P/E of 10.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cryoport, Inc. has 47.1% gross margin and -20.9% operating margin.